2021年度このページを印刷する - 2021年度

2025年1月8日掲載

2021年度
英文論文
  1. Tamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami T, Tamiya A, Sato Y, Saito G, Uchida J, Morita M, Hirashima T, Fukuda Y, Kanazu M, Hosoya K, Suzuki T, Ueno K, Fujimoto D, Kumagai T, Teramukai S. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002. INVESTIGATIONAL NEW DRUGS. 2022 4;40(2):361-369.(田宮朗裕)
 
  1. Matsunuma R, Yamaguchi T, Mori M, Ikari T, Suzuki K, Matsuda Y, Matsumoto Y, Watanabe H, Amano K, Kamura R, Kizawa Y. Predictive Factors for the Development of Dyspnea Within 7 Days After Admission Among Terminally Ill Cancer Patients. AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE. 2022 4;39(4):413-420.(松田能宣)
 
  1. Brown KK, Inoue Y, Flaherty KR, Martinez FJ, Cottin V, Bonella F, Cerri S, Danoff SK, Jouneau S, Goeldner RG, Schmidt M, Stowasser S, Schlenker-Herceg R, Wells AU. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. RESPIROLOGY. 2022 4;27(4):294-300.(井上義一)
 
  1. Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD trial investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. EUROPEAN RESPIRATORY JOURNAL. 2022 3;59(3):2004538.(井上義一)
 
  1. Kinnosuke Matsumoto, Akihiro Tamiya, Yuji Inagaki, Yoshihiko Taniguchi, Yoshinobu Matsuda, Hayato Kawachi, Motohiro Tamiya, Satoshi Tanizaki, Junji Uchida, Kiyonobu Ueno, Takafumi Yanase, Hidekazu Suzuki, Shinji Atagi. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. JOURNAL OF GERIATRIC ONCOLOGY. 2022 3;13(2):207-213.(田宮朗裕)
 
  1. Matsuda Y, Kosugi T, Yamanaka M, Fukumori T, Inoue A, Horiki M, Matsunuma R, Kataoka Y, Kitamura H, Kataoka K, Matsuoka H, Tokoro A, Inoue Y. Expectations of respiratory physicians from psychologists in palliative care for patients with non-cancer respiratory diseases. RESPIRATORY INVESTIGATION. 2022 3;60(2):309-317.(松田能宣)
 
  1. Matsuda Y, Yamaguchi T, Matsumoto Y, Ishiki H, Usui Y, Kako J, Suzuki K, Matsunuma R, Mori M, Watanabe H, Zenda S. Research policy in supportive care and palliative care for cancer dyspnea. JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2022 3;52(3):260-265.(松田能宣)
 
  1. K. Kojima; T. Sakamoto; T. Kasai; H. Yoon; S. Atagi. A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study. JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2022 3;52(3):281-285.(小島健介)
 
  1. Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ OPEN RESPIRATORY RESEARCH. 2022 3;9(1):e001167.(井上義一)
 
  1. Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Histologic transformation of epidermal growth factor receptor-mutated lung cancer. EUROPEAN JOURNAL OF CANCER. 2022 3;16641-50.(田宮朗裕)
 
  1. Satoshi Ishikawa, Yuriko Ozeki, Satomi Suga, Yasuhiko Mukai, Haruka Kobayashi, Erina Inouchi, Shaban A Kaboso, Gebremichal Gebretsadik, Desak Nyoman Surya Suameitria Dewi, Akihito Nishiyama, Yoshitaka Tateishi, Hayato Takihara, Shujiro Okuda, Shiomi Yoshida, Naoaki Misawa, Sohkichi Matsumoto. Monitoring IgG against Mycobacterium tuberculosis proteins in an Asian elephant cured of tuberculosis that developed from long-term latency. SCIENTIFIC REPORTS. 2022 3;12(1):4310.(吉田志緒美)
 
  1. Futami Y, Takeda Y, Koba T, Narumi R, Nojima Y, Ito M, Nakayama M, Ishida M, Yoshimura H, Naito Y, Fukushima K, Takimoto T, Edahiro R, Matsuki T, Nojima S, Hirata H, Koyama S, Iwahori K, Nagatomo I, Shirai Y, Suga Y, Satoh S, Futami S, Miyake K, Shiroyama T, Inoue Y, Adachi J, Tomonaga T, Ueda K, Kumanogoh A. CD14 and lipopolysaccharide-binding protein as novel biomarkers for sarcoidosis by proteomics of serum extracellular vesicles. INTERNATIONAL IMMUNOLOGY. 2022 3;dxac009.(滝本宜之)
 
  1. Corina N D'Alessandro-Gabazza, Taro Yasuma, Tetsu Kobayashi, Masaaki Toda, Ahmed M Abdel-Hamid, Hajime Fujimoto, Osamu Hataji, Hiroki Nakahara, Atsuro Takeshita, Kota Nishihama, Tomohito Okano, Haruko Saiki, Yuko Okano, Atsushi Tomaru, Valeria Fridman D'Alessandro, Miyako Shiraishi, Akira Mizoguchi, Ryoichi Ono, Junpei Ohtsuka, Masayuki Fukumura, Tetsuya Nosaka, Xuenan Mi, Diwakar Shukla, Kensuke Kataoka, Yasuhiro Kondoh, Masaki Hirose, Toru Arai, Yoshikazu Inoue, Yutaka Yano, Roderick I Mackie, Isaac Cann, Esteban C Gabazza. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. NATURE COMMUNICATIONS. 2022 3;13(1):1558.(広瀬雅樹)
 
  1. Cottin V, Tomassetti S, Valenzuela C, Walsh S, Antoniou K, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty K, Johannson KA, Kolb M, Kreuter M, Inoue Y, Jenkins G, Lee JS, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers J, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi L, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson C. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American journal of respiratory and critical care medicine. 2022 3;(井上義一)
 
  1. Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial. The European respiratory journal. 2022 3;2200380.(安宅信二)
 
  1. Arai T; Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, Inoue Y. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Canadian respiratory journal. 2022 3;2022(1):1107673.(新井徹)
 
  1. Enomoto N, Homma S, Inase N, Kondoh Y, Saraya T, Takizawa H, Inoue Y, Ishii H, Taguchi Y, Izumi S, Yamano Y, Tanino Y, Nishioka Y, Toyoshima M, Yokomura K, Imokawa S, Koshimizu N, Sano T, Akamatsu T, Mukae H, Kato M, Hamada N, Chiba H, Akagawa S, Muro S, Uruga H, Matsuda H, Kaida Y, Kanai M, Mori K, Masuda M, Hozumi H, Fujisawa T, Nakamura Y, Ogawa N, Suda T. Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias. THORAX. 2022 2;77(2):143-153.(井上義一)
 
  1. Sakamoto R, Ohtake Y, Kataoka Y, Matsuda Y, Hata T, Otonari J, Yamane A, Matsuoka H, Yoshiuchi K. Efficacy of acceptance and commitment therapy for people with type 2 diabetes: Systematic review and meta-analysis.JOURNAL OF DIABETES INVESTIGATION. 2022 2;12(3):262-270.(松田能宣)
 
  1. Langford B, Diamantopoulos A, Maher TM, Inoue Y, Rohr KB, Baldwin M. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework. ADVANCES IN THERAPY. 2022 2;39(2):1045-1054.(井上義一)
 
  1. Murakami Y, Tamiya A, Taniguchi Y, Adachi Y, Enomoto T, Azuma K, Inagaki Y, Kouno S, Matsuda Y, Okishio K, Atagi S. Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab. THORACIC CANCER. 2022 2;13(4):593-601.(田宮朗裕)
 
  1. Okuma Y, Shimokawa M, Hashimoto K, Mizutani H, Wakui H, Murakami S, Atagi S, Minato K, Seike M, Ohe Y, Kubota K; Tokyo Cooperative Oncology Group. Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901). FUTURE ONCOLOGY. 2022 2;18(5):523-531.(安宅信二)
 
  1. Matsuoka H, Clark K, Fazekas B, Oyamada S, Brown L, Ishiki H, Matsuda Y, Hasuo H, Ariyoshi K, Lee J, Le B, Allcroft P, Kochovska S, Fujiwara N, Miyaji T, Lovell M, Agar M, Yamaguchi T, Satomi E, Iwase S, Phillips J, Koyama A, Currow DC. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ OPEN. 2022 2;12(2):(松田能宣)
 
  1. Kanako Katayama, Toru Arai, Takehiko Kobayashi, Sayoko Shintani, Naoko Takeuchi, Yoshinobu Matsuda, Chikatoshi Sugimoto, Yasushi Inoue, Maiko Takeda, Takahiko Kasai, Masanori Akira, Yoshikazu Inoue. Pleuroparenchymal Fibroelastosis with a Predominantly Airway-centered Distribution: A Late Complication of Chemotherapy. INTERNAL MEDICINE. 2022 2;61(4):7402-21.(片山加奈子)
 
  1. Enomoto T, Tamiya A, Matsumoto K, Adachi Y, Azuma K, Inagaki Y, Kouno S, Taniguchi Y, Saijo N, Okishio K, Atagi S. Correction to: Nivolumab treatment beyond progressive disease in advanced non‑small cell lung cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2022 2;(田宮朗裕)
 
  1. Naito T, Uchino J, Kojima T, Matano Y, Minato K, Tanaka K, Mizukami T, Atagi S, Higashiguchi T, Muro K, Takayama K, Furuse J, Morishima E, Takiguchi T, Tamura K. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. CANCER. 2022 2;(安宅信二)
 
  1. Yu Kurahara, Yoshinobu Matsuda, Kazunari Tsuyuguchi, Akihiro Tokoro. Delirium in Patients with COVID-19 in Japan. Internal medicine (Tokyo, Japan). 2022 2;10(2169):9013-21.(倉原優)
 
  1. Arai T, Hirose M, Kagawa T, Hatsuda K, Inoue Y. Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis. JOURNAL OF THORACIC DISEASE. 2022 2;14(2):278-294.(新井徹)
 
  1. Hiroko Kitaoka, Takayuki Takimoto, Takashi Kijima. Static end-tidal expiratory computed tomography visualizes only a static type of expiratory central airway collapse. RESPIRATORY INVESTIGATION. 2022 1;60(1):182-183.(滝本宜之)
 
  1. Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. RESPIROLOGY. 2022 1;27(1):66-75.(井上義一)
 
  1. Takayuki Takimoto. Post-capillary pulmonary hypertension in patients with interstitial lung disease: An important but overlooked phenomenon. RESPIRATORY INVESTIGATION. 2022 1;60(1):180-181..(滝本宜之)
 
  1. Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, Kenji Sugio, Masahiro Tsuboi, Isamu Okamoto, Yasuo Iwamoto, Noriaki Sakakura, Shunichi Sugawara, Shinji Atagi, Toshiaki Takahashi, Hidetoshi Hayashi, Morihito Okada, Hidetoshi Inokawa, Hiroshige Yoshioka, Kazuhisa Takahashi, Masahiko Higashiyama, Ichiro Yoshino, Kazuhiko Nakagawa, West Japan Oncology Group. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT). JOURNAL OF CLINICAL ONCOLOGY. 2022 1;40(3):231-241.(安宅信二)
 
  1. Majem M, Goldman JW, John T, Grohe C, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Li S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Atagi S, Zeng L, Kulkarni D, Medic N, Tsuboi M, Herbst RS, Wu YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022 1;(安宅信二)
 
  1. Kawachi H, Tamiya M, Matsumoto K, Tamiya A, Yanase T, Tanizaki S, Kumagai T. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. INVESTIGATIONAL NEW DRUGS. 2022 1;40(3):634-642.(田宮朗裕)
 
  1. Yu Kurahara, Takehiko Kobayashi, Kazunobu Tachibana, Kazunari Tsuyuguchi. The feasibility of rifampicin Re-administration in patients with tuberculosis and Clostridioides difficile infection. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy. 2022 1;28(4):558-562.(倉原優)
 
  1. Baldi BG, Radzikowska E, Cottin V, Dilling DF, Ataya A, Carvalho CRR, Harari S, Koslow M, Grutters JC, Inoue Y, Gupta N, Johnson SR. COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition. Chest. S0012-3692(21)05166-7.(井上義一)
 
  1. Suzuki K, Ikari T, Matsunuma R, Matsuda Y, Matsumoto Y, Miwa S, Mori M, Yamaguchi T, Watanabe H, Tanaka K. The Possibility of Conducting a Clinical Trial on Palliative Care: A Survey of Whether a Clinical Study on Cancer Dyspnea Is Acceptable to Cancer Patients and Their Relatives. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2021 12;62(6):1262-1272.(松田能宣)
 
  1. Hiroyasu Kaneda, Kenji Sawa, Haruko Daga, Asuka Okada, Yuki Nakatani, Shinji Atagi, Kyoichi Okishio, Yoko Tani, Yoshiya Matsumoto, Koichi Ogawa, Kenji Nakahama, Motohiro Izumi, Shigeki Mitsuoka, Tomoya Kawaguchi. Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. INVESTIGATIONAL NEW DRUGS. 2021 12;39(6):1598-1603.(沖塩協一)
 
  1. Miyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Takayasu Kurata, Akimasa Sekine, Atsushi Horiike, Tatsuro Fukuhara, Shunichi Sugawara, Shigeki Umemura, Hideo Saka, Isamu Okamoto, Nobuyuki Yamamoto, Hiroshi Sakai, Kazuma Kishi, Nobuyuki Katakami, Hidehito Horinouchi, Toyoaki Hida, Hiroaki Okamoto, Shinji Atagi, Tatsuo Ohira, Shi Rong Han, Kazuo Noguchi, Victoria Ebiana, Katsuyuki Hotta. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. CANCER SCIENCE. 2021 12;112(12):5000-5010.(安宅信二)
 
  1. Ishiki H, Hasuo H, Matsuda Y, Matsuoka H, Hiramoto S, Higuchi M, Yoshida K, Tokoro A, Hatano Y, Hori T, Kinkawa J, Nojima M. Prevalence of myofascial pain syndrome and efficacy of trigger point injection in patients with incurable cancer. A multicenter, prospective observational study. (MyCar study). PAIN MEDICINE. 2021 12;10(1093):350.(松田能宣)
 
  1. T. Arai; T. Kagawa; Y. Sasaki; R. Sugawara; C. Sugimoto; K. Tachibana; Y. Fujita; S. Hayashi; Y. Inoue. Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. CANADIAN RESPIRATORY JOURNAL. 2021 12;2021(1):4595019.(新井徹)
 
  1. Murakami H, Horinouchi H, Harada H, Sobue T, Kato T, Atagi S, Kozuki T, Tokito T, Oizumi S, Seike M, Ohashi K, Mio T, Sone T, Jinushi M, Tsuboi M. Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study. LUNG CANCER. 2021 12;165152-163.(安宅信二)
 
  1. Koji Azuma, Takayuki Takimoto, Takahiko Kasai, Masaki Hirose, Kazuyoshi Hatsuda, Chikatoshi Sugimoto, Toru Arai, Masanori Akira, Yoshikazu Inoue. Diagnostic yield and safety of bronchofiberscopy for pulmonary alveolar proteinosis. RESPIRATORY INVESTIGATION. 2021 11;59(6)757-765.(滝本宜之)
 
  1. Mori M, Kawaguchi T, Imai K, Yokomichi N, Yamaguchi T, Suzuki K, Matsunuma R, Watanabe H, Maeda I, Matsumoto Y, Matsuda Y, Morita T; EASED Investigators.  Visualizing How to Use Parenteral Opioids for Terminal Cancer Dyspnea: A Pilot, Multicenter, Prospective, Observational Study. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2021 11;62(5):936-948.(松田能宣)
 
  1. Yoshihiko Taniguchi. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). LUNG CANCER. 2021 11;16186-93.(谷口善彦)
 
  1. Yu Kurahara, Takehiko Kobayashi, Sayoko Shintani, Yoshinobu Matsuda, Akihiro Tamiya, Reiko Sugawara, Toru Arai, Kazunobu Tachibana, Kyoichi Okishio, Hideo Matsui, Kazunari Tsuyuguchi. Clinical characteristics of COVID-19 in Osaka, Japan: Comparison of the first-third waves with the fourth wave. RESPIRATORY INVESTIGATION. 2021 11;59(6):810-818.(倉原優)
 
  1. Teiko Sakurai, Toru Arai, Masaki Hirose, Kensuke Kojima, Tetsuki Sakamoto, Yoshinobu Matsuda, Chikatoshi Sugimoto, Hyung-Eun Yoon, Yoshikazu Inoue. Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung. in lymphangioleiomyomatosisORPHANET JOURNAL OF RARE DISEASES. 2021 11;16(1):466.(広瀬雅樹)
 
  1. Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y. The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. EUROPEAN RESPIRATORY JOURNAL. 2021 11;2101790.(井上義一)
 
  1. Ryota Shintani, Akimasa Sekine, Kota Murohashi, Ryota Otoshi, Takeo Kasuya, Tsuneyuki Oda, Tomohisa Baba, Shigeru Komatsu, Takashi Ogura, Yoshikazu Inoue. 　Successful Treatment of Chylothorax and Chylopericardium by Radiotherapy in Lung Cancer. Internal medicine (Tokyo, Japan). 2021 11;8293-21.(新谷亮太)
 
  1. Asako, Mizuki; Matsunaga, Hitomi; Nakahara, Wataru; Ikeda, Mako; Mima, Fuka; Minami, Ryota; Sekiguchi, Masahiro; Oka, Kazumasa; Wada, Naoki; Suzuki, Katsuhiro; Yoshizawa, Kazutaka; Sakagami, Takuro; Ueda, Shuji. Mycobacterial lymphadenitis without granuloma formation in a patient with anti-interferon-gamma antibodies. INTERNATIONAL JOURNAL OF HEMATOLOGY. 2021 NOV;114(5):630-635.( 鈴木克洋)
 
  1. Maeda I, Satomi E, Kiuchi D, Nishijima K, Matsuda Y, Tokoro A, Tagami K, Matsumoto Y, Naito A, Morita T, Iwase S; Phase-R N/V Study Group, Otani H, Odagiri T, Watanabe H, Mori M, Matsuda Y, Nagaoka H, Mayuzumi M, Kanai Y, Sakamoto N, Ariyoshi K. Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study. SUPPORTIVE CARE IN CANCER. 2021 10;29(10):5831-5838.(所昭宏)
 
  1. Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. RESPIRATORY INVESTIGATION. 2021 10;59(6):709-740.(井上義一)
 
  1. Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. RESPIRATORY MEDICINE. 2021 10;187106574.(井上義一)
 
  1. K. Kojima; T. Sakamoto; T. Kasai; T. Kagawa; H. Yoon; S. Atagi. PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC. SCIENTIFIC REPORTS. 2021 9;11(1):17522.(小島健介)
 
  1. Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Okamoto M, Akashi Y, Kizawa Y. Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J Study): A Post Hoc Analysis. JOURNAL OF CLINICAL MEDICINE. 2021 9;10(18):４１９３.(所昭宏)
 
  1. 55. Hasuo H, Ishiki H, Matsuda Y, Matsuoka H, Hiramoto S, Kinkawa J, Nojima M. The Usefulness of the Armchair Sign for the Diagnosis of Psychosomatic-Prone Myofascial Pain Syndrome in Patients with Incurable Cancer: A Secondary Analysis of a Prospective Multicenter Observational Clinical Study. PALLIATIVE MEDICINE REPORTS. 2021 9;2(1):250-254.(松田能宣)
 
  1. Hiroshi Sakai, Masahiro Morise, Terufumi Kato, Shingo Matsumoto, Tomohiro Sakamoto, Toru Kumagai, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroshi Tanaka, Kenichi Chikamori, Naofumi Shinagawa, Hiroaki Takeoka, Rolf Bruns, Josef Straub, Karl Maria Schumacher, Paul K Paik. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2021 8;51(8):1261-1268.(安宅信二)
 
  1. Mizukoshi F, Kobayashi N, Kirikae F, Ohta K, Tsuyuguchi K, Yamada N, Inoue Y, Horiba M, Kawata N, Ichinose A, Miyoshi-Akiyama T, Kiritani R, Funatogawa K, Kirikae T. Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan. MSPHERE. 2021 8;6(4):e00978-20.(露口一成)
 
  1. Hasuo H, Matsuoka H, Matsuda Y, Fukunaga M. The Immediate Effect of Trigger Point Injection With Local Anesthetic Affects the Subsequent Course of Pain in Myofascial Pain Syndrome in Patients With Incurable Cancer by Setting Expectations as a Mediator. FRONTIERS IN PSYCHIATRY. 2021 8;12:592776.(松田能宣)
 
  1. Yukihiro Nakamura, Takayuki Takimoto, Takehiko Kobayashi, Kazunobu Tachibana, Takahiko Kasai, Masanobu Akira, Toru Arai, Yoshikazu Inoue. Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. RESPIRATORY MEDICINE CASE REPORTS. 2021 8;34101498.(滝本宜之)
 
  1. Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. INVESTIGATIONAL NEW DRUGS. 2021 8;39(4):1106-1112.(田宮朗裕)
 
  1. Yu Kurahara. The Detachment Process of Aspergilloma Formation. INTERNAL MEDICINE. 2021 7;60(13):2153-2154.(倉原優)
 
  1. Yu Kurahara. Massive Bronchorrhea. INTERNAL MEDICINE. 2021 7;60(13):2155-2156.(倉原優)
 
  1. T.Arai; H. Matsuoka; M. Hirose; H. Kida; S.Yamamoto; Y. Ogata; M. Mori; K. Hatsuda; C. Sugimoto; K. Tachibana; M. Akira; Y. Inoue. Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. BMJ OPEN RESPIRATORY RESEARCH. 2021 7;8(1):e000889.(新井徹)
 
  1. Udagawa H, Sugiyama E, Harada T, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Kida H, Satouchi M, Maeno K, Inoue A, Yoh K, Yamane Y, Urata Y, Yoshioka H, Yamanaka T, Goto K. Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). TRANSLATIONAL LUNG CANCER RESEARCH. 2021 7;10(7):3059-3070.(安宅信二)
 
  1. Takatoshi Enomoto, Takayuki Takimoto, Tomoko Kagawa, Kazunobu Tachibana, Chikatoshi Sugimoto, Toru Arai, Teiko Sakurai, Takahiko Kasai, Masanori Akira, Seiji Hayashi, Yoshikazu Inoue. Histologically Proven Dendriform Pulmonary Ossification: A Five-case Series. INTERNAL MEDICINE. 2021 7;60(14):2261.(滝本宜之)
 
  1. Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, Iwasawa S, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Hirano K, Kokubo M, Yamamoto N. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. INVESTIGATIONAL NEW DRUGS. 2021 6;39(3):853-859.(田宮朗裕)
 
  1. Tamiya A, Isa SI, Taniguchi Y, Nakagawa H, Atagi S, Ando M, Koh Y. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). CLINICAL LUNG CANCER. 2021 5;22(3):e336-e341.(田宮朗裕)
 
  1. Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. SCIENTIFIC REPORTS. 2021 5;11(1):9629.(田宮朗裕)
 
  1. Matsuda Y, Morita T, Oyamada S, Ariyoshi K, Yamaguchi T, Iwase S. Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15). BMJ OPEN. 2021 5;11(5):(松田能宣)
 
  1. Enomoto T, Inoue Y, Adachi Y, Kouno S, Inagaki Y, Azuma K, Katayama K, Takeuchi N, Matsuda Y.  Limitations of End-Tidal CO2 Measured with a Portable Capnometer to Estimate PaCO2 for Patients with Respiratory Disease. TURKISH THORACIC JOURNAL. 2021 5;22(3):212-216.(井上義一)
 
  1. Matsumoto K, Nakamura Y, Inagaki Y, Taniguchi Y, Tamiya A, Matsuda Y, Kasai T, Atagi S. Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: An autopsy case report. THORACIC CANCER. 2021 4;12(7):1137-1140.(安宅信二)
 
  1. Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, Kanazu M, Mori M, Nagata K, Fukuda I, Tamiya M. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC CANCER. 2021 4;21(1):346.(田宮朗裕)
 
  1. Matsumoto K, Tamiya A, Matsuda Y, Taniguchi Y, Atagi S, Kawachi H, Tamiya M, Tanizaki S, Uchida J, Ueno K, Yanase T, Suzuki H, Hirashima T. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. TRANSLATIONAL LUNG CANCER RESEARCH. 2021 4;10(4):1642-1652.(田宮朗裕)
 
  1. Takehiko Kobayashia, Kazunari Tsuyuguchib, Shiomi Yoshidab, Yohei Kimuraa,c, Taisuke Tsujia,d, Shojiro Minomoa, Yu Kuraharaa, Yoshikazu Inouee, Katsuhiro Suzukia. Resumption/Efficacy and safety of azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects by clarithromycin-containing regimen. RESPIRATORY INVESTIGATION. 2021 3;59(2):212-217.(小林岳彦)
 
  1. Hiraku Tsujimoto, Yuki Kataoka, Yukihito Sato, Masahiro Banno, Emi Tsujino-Tsujimoto, Yukiyoshi Sumi, Ryuichi Sada, Takashi Fujiwara, Yoichi Ohtake, Junji Kumasawa, Haruki Imura, Yoshinobu Matsuda, Ryuhei So, Tomoko Kagawa, Takashi Yoshioka, Yu Uneno, Hiroyuki Nagano, Mai Akazawa, Takunori Hozumi, Yasushi Tsujimoto. A model six-month workshop for developing systematic review protocols at teaching hospitals: action research and scholarly productivity. BMC MEDICAL EDUCATION. 2021 2;21(1):1-8.(香川智子)
 
和文原著・著書等
1. 露口一成. プライマリケア医のためのこれからの咳の診かた 結核・非結核性抗酸菌症. 治療. 2022;104(4):462-466.
2. 角甲純, 中村陽一, 西智弘, 高木雄亮, 松田能宣, 渡邊紘章, 笠原庸子, 合屋将, 小原弘之, 森雅紀, 山口崇. 呼吸困難を有する慢性進行性疾患患者に対する送風療法の有効性：システマティックレビュー・メタ解析. Palliative Care Research. 2022;17(1):33-42.
3. 倉原優. 新型コロナワクチンによるアナフィラキシーの症例定義. 日本医事新報. 2022;(5057):56.
4. 倉原優. 新型コロナとロシア軍. 日本医事新報. 2022;(5108):58.
5. 倉原優. 日本が直面する高齢者の風邪診療に. 総合診療. 2022;32(3):157.
6. 倉原優. 吸入ステロイドと緑膿菌の関係. J-IDEO. 2022;6(2):360-361.
7. 倉原優. 大阪府の新型コロナ死者が多い理由. 日本医事新報. 2022;(5106):54.
8. 倉原優. クロファジミンの歴史. 結核. 2022;97(2):105-110.
9. 日本結核・非結核性抗酸菌症学会治療委員会. イソニコチン酸ヒドラジドが使用できない場合の結核治療について. 結核. 2022;97(2):125-127.
10. 大槻登季子. 結核院内感染対策　
結核病棟を有する医療施設における感染管理認定看護師の役割. 保健師・看護師の結核展望. 2022;118(59):51～58.
11. 井上義一, 新井徹, 清水重喜, 澄川裕充. 慢性線維化性間質性肺炎における血液バイオマーカー：MDD診断での位置づけ. 呼吸器内科. 2022;41(2):172-179.
12. 倉原優. 気管支喘息、COPD急性増悪.  改訂版ER実践ハンドブック. 2022;
13. 露口一成. 結核と非結核性抗酸菌症Up to Date-診断、治療、感染対策、発病予防 　多剤耐性結核の治療. 医学のあゆみ. 2022;280(6):641-646.
14. 稲垣雄士. 炎症性腸疾患を基礎疾患にもつがん患者への免疫チェックポイント阻害薬の治療. 医学論文の読み方2.0 論文を批判的に吟味し臨床適用するためのLetterの書き方. 2022;P154-160.
15. 倉原優. 感染者の隔離期間の短縮が再び議論へ. 日本医事新報. 2022;(5100):56-57.
16. 倉原優. 水道水を抗酸菌染色したらどうなる？. J-IDEO. 2022;6(1):156-157.
17. 倉原優. コロナ第5波の収束要因と今後の医療提供体制の展望. コミュニティケア. 2022;24(2):32-35.
18. 倉原優. イスコチン. なんで使うの？そのくすり.. 2022;P40-43.
19. 倉原優. リファンピシン. なんで使うの？そのくすり.. 2022;P44-46.
20. 倉原優. レジデントのための専門科コンサルテーション. 臨床外科. 2022;77(1):50.
21. 菅野康二, 長谷川貴昭, 稲田修士, 原島沙季, 松田能宣, 谷向仁. がん治療におけるせん妄への対応. 癌と化学療法. 2022;49(1):7.
22. 井上　康.  33.「慢性呼吸不全」. 呼吸器内科学レビュー2022-‘23. 2021; P.240-246.
23. 倉原優. 医師の賃金を議論する前に. 日本医事新報. 2021;(5095):58.
24. 倉原優. 新型コロナ病棟ナース戦記. 新型コロナ病棟ナース戦記. 2021;
25. 倉原優. 喀血・血痰. 総合診療. 2021;31(12):1484-1487.
26. 露口一成. 粟粒結核. 別冊日本臨床　呼吸器症候群（第3版）Ⅳ. 2021;2084～87.
27. 松田能宣 . 終末期医療. みんなの呼吸器Respica. 2021;(冬季増刊号):123-128.
28. 倉原優. いつも悩ましい、片側大量胸水. J-IDEO. 2021;5(6):944-945.
29. 倉原優. 胸水. 呼吸器ジャーナル. 2021;69(4):564-79.
30. 玉舍　学. 剥離性間質性肺炎(DIP). 呼吸器症候群（第3版）Ⅲ. 2021;77-80.
31. 倉原優. 世の中にトンデモ医療本があふれる理由. 日本医事新報. 2021;(5090):60.
32. 小林岳彦. 特集 呼吸器救急と呼吸管理. 呼吸器ジャーナル. 2021;69(4):496-503.
33. 澄川裕充, 清水重喜. 病態や形態学的な特徴を示す言葉と疾患名としての用語の使い分けは？. 画像診断. 2021;41(13):1401-1409.
34. 倉原優. ワクチン・検査パッケージ戦略が現実に. 日本医事新報. 2021;(5087):56.
35. 倉原優. 医師や学会のSNSアカウントのメリット・デメリット. 日本医事新報. 2021;(5084):63-64.
36. 沖塩協一. 特集 肺がん. 健康ライフさかい. 2021;(23):P1-P5.
37. 浅見貴弘, 森本耕三, 小林岳彦, 南宮湖, 長谷川直樹. 市民公開講座参加者のアンケートからみる
    肺非結核性抗酸菌症の現状と課題. 結核. 2021;96(6):153-160.
38. 倉原優. ついに実現、吸入アミカシン. J-IDEO. 2021;5(5):792-793.
39. 露口一成. ポストコロナに備えるべき日常感染症－動向・対策・治療の基本まで　⑤結核・多剤耐性結核. 感染と抗菌薬. 2021;24(3):179-183.
40. 日本結核・非結核性抗酸菌症学会治療委員会. 多剤耐性結核の治療におけるリネゾリドの利用について. 結核. 2021;96(6):183-185.
41. 松田能宣. 喘息の心理療法、心身医学的治療. アレルギーの臨床. 2021;41(10):868～871.
42. 内藤明美, 森田達也, 田村恵子, 大屋清文, 松田能宣, 田上恵太, 柏木秀行, 大谷弘行. スピリチュアルペインに関する緩和ケア医と精神科医の認識に関する全国調査. Palliative Care Research. 2021;16(2):115～122.
43. 井上真一郎, 谷向仁, 松田能宣, 奥山徹. 緩和ケアにおけるせん妄. 臨床精神医学. 2021;50(8):829～837.
44. 竹内奈緒子, 新井徹, 井上義一. 膠原病肺、肺胞蛋白症（PAP）. 見る診るわかる！　胸部画像診断. 2021;130～138、175～181.
45. 倉原優. 新型コロナワクチンに関する医療従事者のデマゴーグ. 日本医事新報. 2021;(5075):62.
46. 倉原優. 肺非結核性抗酸菌症ガイドライン（ATS/ERS/ESCMID/IDSA）.  臨床と微生物. 2021;48(4):63-9.
47. 山田　多加. 多職種協働で取り組む医療安全活動の効果. 医療の広場. 2021;61(7):31-34.
48. 倉原優. コロナ禍のTwitter－ナッジ理論の後押しと抑うつ傾向. 日本医事新報. 2021;(5071):63-64.
49. 小林　雅. 呼吸器疾患に特化した当院における、心エコーでの計測値と高感度TnI値との相関性の検討. 医療の広場. 2021;61(6):31-34.
50. 小林雅, 上西珠実, 福田和弘, 水谷美香, 土田麗央奈, 濱奈緒子, 佐々木達彦, 樋口冨士夫, 玉舍学, 笠井孝彦. 呼吸器疾患に特化した当院における、心エコーでの計測値と高感度TnI値との相関性の検討. 医療の広場. 2021;61(6):31-34.
51. 倉原優. マスコミに振り回される新型コロナワクチン施策. 日本医事新報. 2021;(5067):59-60.
52. 所昭宏. 新型コロナウイルス感染症受け入れ病院における心療内科医活動記. 日本心療内科学会誌. 2021;25(2):117-119.
53. 倉原優. 喘息増悪時の最適治療は？. 救急外来、ここだけの話. 2021;P105-110.
54. 倉原優. 薬剤性肺障害でしょうか？感染症でしょうか？. J-IDEO. 2021;5(4): 596-597.
55. 倉原優. 大阪府におけるコロナ第4波の病床逼迫. 日本医事新報. 2021;(5061):58.
56. 倉原優. ポケット呼吸器診療2021. ポケット呼吸器診療2021. 2021;
57. 倉原優. 気管支喘息—アクションプランで救急外来受診を減らそう！. medicina. 2021;58(4):106-9.
58. 沖塩協一. 免疫チェックポイント阻害薬による癌治療の. 堺市医師会報. 2021;(70):P6-P.11.
59. 倉原優. 喘息・COPDの治療薬. レジデントノート. 2021;22(18):3106-3114.
60. 倉原優. 慢性咳嗽. medicina. 2021;58(2):1983-97.
 
ページトップへ